The specificity of antisense approaches is much debated and has hampered their development for clinical therapeutics. In the August 14 Proceedings of the National Academy of Sciences, Yee Cho and ...

Scientists have developed a DNA nanoflower that delivers chemotherapy and gene therapy directly to breast cancer cells, ...

In short, when antisense RNA matches up with and binds to messenger RNA (mRNA), or to a precursor strand called pre-mRNA, it stops the latter from conveying the instructions for making proteins.

The antisense oligonucleotide therapeutics market was valued at US$17.46 billion in 2021 and is projected to grow at a CAGR of 13.71% during the forecast period 2022-2032.

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Antisense & RNAi Therapeutics Market Antisense & RNAi Therapeutics Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market by Technology, Route of Administration, ...

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2 (CAPN2), a calcium-activated protease believed to play a role in ALS disease progression.

The article, “Effects of local reduction of endogenous α-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice ...

Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi January 07, 2025 10:00 AM Eastern Standard Time ...